iCAD to Present at iAccess Alpha Buyside Best Ideas Fall Conference 2024
Curated by THEOUTPOST
On Thu, 12 Sept, 12:06 AM UTC
2 Sources
2 Sources
[1]
iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 By Investing.com
NASHUA, N.H., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: NASDAQ:ICAD) (iCAD or the Company) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 on September 24 and 25, 2024. CEO, Dana Brown and CFO, Eric Lonnqvist will deliver a company presentation at 11:00 am ET on September 24, and host one-on-one meetings the following day, September 25. To learn more about the iAccess Alpha Buyside Best Ideas Fall Conference 2024, or to register and schedule a one-on-one meeting with iCAD, please visit the conference website at https://www.iaccessalpha.com/home. The iCAD presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/3064/51217. The iCAD presentation will also be available on the company's investor relations website under the Events & Earnings Calls tab. About iAccess Alpha iAccess Alpha hosts virtual investor conferences, where presenting companies are recommended by investors. The conference format spans two days, with company webcast presentations on day one, followed by one-on-one meetings with company management teams on day two. About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. Forward-Looking Statements Certain statements contained in this News Release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI ®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words believe, demonstrate, intend, expect, estimate, will, continue, anticipate, likely, seek, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
[2]
iCAD to Participate in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 - icad (NASDAQ:ICAD)
NASHUA, N.H., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. ICAD ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today that management is participating in the iAccess Alpha Buyside Best Ideas Fall Conference 2024 on September 24 and 25, 2024. CEO, Dana Brown and CFO, Eric Lonnqvist will deliver a company presentation at 11:00 am ET on September 24, and host one-on-one meetings the following day, September 25. To learn more about the iAccess Alpha Buyside Best Ideas Fall Conference 2024, or to register and schedule a one-on-one meeting with iCAD, please visit the conference website at https://www.iaccessalpha.com/home. The iCAD presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/3064/51217. The iCAD presentation will also be available on the company's investor relations website under the Events & Earnings Calls tab. About iAccess Alpha iAccess Alpha hosts virtual investor conferences, where presenting companies are recommended by investors. The conference format spans two days, with company webcast presentations on day one, followed by one-on-one meetings with company management teams on day two. About iCAD, Inc. iCAD, Inc. ICAD is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD's industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company's products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company's products, and future prospects for the Company's technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company's ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe," "demonstrate," "intend," "expect," "estimate," "will," "continue," "anticipate," "likely," "seek," and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov. CONTACTS Media inquiries: pr@icadmed.com Investor Inquiries: John Nesbett/Rosalyn Christian IMS Investor Relations icad@imsinvestorrelations.com Market News and Data brought to you by Benzinga APIs
Share
Share
Copy Link
iCAD, Inc., a global medical technology leader in cancer detection and therapy solutions, announces its participation in the upcoming iAccess Alpha Buyside Best Ideas Fall Conference 2024. The company's CEO, Stacey Stevens, will deliver a virtual presentation on September 12, 2023.
iCAD Announces Participation in Prestigious Investor Conference
iCAD, Inc. (NASDAQ: ICAD), a prominent player in the medical technology sector specializing in cancer detection and therapy solutions, has announced its participation in the upcoming iAccess Alpha Buyside Best Ideas Fall Conference 2024 1. This virtual event, scheduled for September 12, 2023, provides an excellent platform for iCAD to showcase its innovative technologies and strategic vision to potential investors and industry analysts.
Key Details of the Presentation
The company's Chief Executive Officer, Stacey Stevens, will be at the forefront of this presentation, scheduled to take place on Tuesday, September 12, 2023, at 11:00 a.m. Eastern Time 2. This timing suggests a prime slot during the conference, potentially indicating the high level of interest in iCAD's offerings and market position.
Accessing the Presentation
For those interested in attending the virtual presentation, iCAD has made provisions for easy access. The live webcast of the presentation will be available through the company's website in the "Events and Presentations" section of the Investors page 1. This approach ensures that a wide audience, including those unable to attend the conference directly, can benefit from the insights shared during the presentation.
About iCAD, Inc.
iCAD, Inc. stands as a global medical technology leader, focusing on innovative cancer detection and therapy solutions 2. The company's portfolio includes cutting-edge artificial intelligence-based technologies for cancer detection and radiation therapy. These solutions are designed to improve patient outcomes, reduce healthcare costs, and offer more effective treatment options.
Significance of the Conference Participation
The iAccess Alpha Buyside Best Ideas Fall Conference is known for featuring promising companies with significant growth potential. iCAD's participation in this event underscores its position as a noteworthy player in the medical technology sector. It provides an opportunity for the company to articulate its business strategy, highlight recent achievements, and outline future growth prospects to a discerning audience of investors and analysts.
Potential Impact on Investors
For current and potential investors, this presentation offers a valuable opportunity to gain deeper insights into iCAD's operations, technological advancements, and market positioning. The information shared during such events can often influence investment decisions and market perceptions, potentially impacting the company's stock performance and valuation.
Looking Ahead
As the conference date approaches, market watchers and healthcare technology enthusiasts will be keen to hear about iCAD's latest developments in cancer detection and therapy solutions. The presentation may also touch upon the company's plans to navigate the evolving healthcare landscape and capitalize on emerging opportunities in the medical technology sector.
iCAD Announces Q3 2024 Financial Results Release and Participation in Craig-Hallum Conference
iCAD, a leader in AI-powered cancer detection, sets date for Q3 2024 financial results and plans to attend the Craig-Hallum Alpha Select Conference, showcasing its commitment to AI innovation in healthcare.
2 Sources
2 Sources
iCAD Showcases Advanced AI Solutions for Breast Cancer Detection at SABCS and RSNA 2024
iCAD presents groundbreaking AI-driven breast cancer research at SABCS 2024 and unveils new partnerships and FDA-cleared technologies at RSNA 2024, advancing early detection and risk assessment across diverse populations.
4 Sources
4 Sources
iCAD and Cascaid Health Partner to Revolutionize Breast Cancer Detection with AI-Powered Solutions
iCAD, Inc. showcases groundbreaking AI technologies for breast health at RSNA 2024, including FDA-cleared ProFound Detection Version 4 and a new partnership with Cascaid Health to expand access to AI-driven breast health solutions.
2 Sources
2 Sources
Q2 2024 Financial Results: A Mixed Bag for Tech and Healthcare Companies
Several companies, including iCAD, SKYX, Acrivon Therapeutics, and Janover, have reported their second quarter 2024 financial results. While some companies showed growth, others faced challenges in revenue and net losses.
6 Sources
6 Sources
Spectral AI Announces Q3 2024 Financial Results Conference Call
Spectral AI, an AI company focused on medical diagnostics in wound care, has scheduled its 2024 third quarter financial results and conference call for November 6, 2024.
2 Sources
2 Sources
Your one-stop AI hub
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
The Outpost
Keep in touch
© 2025 TheOutpost.AI All rights reserved